X0609 4 2026-09-15 0001563880 Trevi Therapeutics, Inc. TRVI 0001448914 Heffernan Michael Thomas false C/O TREVI THERAPEUTICS, INC. 195 CHURCH STREET, 16TH FLOOR NEW HAVEN CT 06510 true false false false true Common Stock 2026-09-15 4 M false 18421 3.04 A 24772 D Common Stock 2026-09-15 4 S false 18321 15.09 D 6451 D Common Stock 2026-09-15 4 S false 100 15.88 D 6351 D Common Stock 2026-09-15 4 M false 21052 3.33 A 27403 D Common Stock 2026-09-15 4 S false 20952 15.09 D 6451 D Common Stock 2026-09-15 4 S false 100 15.88 D 6351 D Stock Option (right to buy) 3.04 2026-09-15 4 M false 18421 0.00 D Common Stock 18421 0 D Stock Option (right to buy) 3.33 2026-09-15 4 M false 21052 0 D Common Stock 21052 0 D This exercise of stock options and subsequent sale were effected pursuant to a Rule 10b5-1 trading plan that was adopted on June 16, 2026. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.80 to $15.69 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. These options were granted on February 28, 2017. The 18,421 shares of common stock underlying the options vested over four years from the date of grant in equal quarterly installments. These options, which were awarded on February 28, 2017, would otherwise expire and become forfeitable on February 27, 2027. These options were granted on December 20, 2017. The 21,052 shares of common stock underlying the options vested over four years from the date of grant in equal quarterly installments. These options, which were awarded on December 20, 2017, would otherwise expire and become forfeitable on December 19, 2027. /s/ Christopher Galletta, attorney-in-fact 2026-09-17